Carolinas HealthCare System

Research and Clinical Trials

Breast - Female 

Brief Description PrincipalĀ Investigator
To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients with positive SLN(s) after completion of neoadjuvant chemotherapy
White, Richard L 
This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer White, Richard L 
Celera Corporation: Comparison of Breast Cancer Somatic Gene Expression Measurements for Potential O Calhoun, Ben 
The purpose of this study is to observe the cosmetic outcomes, patient satisfaction, and complications after skin sparing mastectomy with preservation of the nipple areolar complex. White, Richard L 
Primary: To assess breast health knowledge among Latino women who have attended a "Living Room Visit" breast education program by comparing pre and post-interventional surveys administered to women immediately before and after education and three months after intervention.
Secondary: To evaluate patterns of survey responses and explore quantitatively the overall feasibility of the community assessment program in terms of completion rate of the 3 month follow-up survey.
Carrizosa, Daniel 
This trial is studying how well hormone therapy or chemotherapy before surgery based on gene expression analysis works in treating patients with breast cancer. Limentani, Steven A 
The primary aim of this Phase III randomized clinical trial is to determine whether trastuzumab given concurrently with radiation therapy (RT) is more beneficial in preventing subsequent ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS, when compared with RT alone in women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy.
Limentani, Steven A 
To determine whether the addition of trastuzumab to chemotherapy (TC or AC?_WP) improves invasive disease-free survival (IDFS) in women with resected node-positive or high-risk node-negative breast cancer which is reported as HER2-low by all HER2 testing performed. Limentani, Steven A 
NSABP B-50-I: A randomized, multicenter, open-label phase III study to evaluate the eff Limentani, Steven A 
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer


Sharp, Hadley 
To compare invasive disease-free survival (DFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer randomized to either chemotherapy plus 1 year of trastuzumab plus pertuzumab or chemotherapy plus 1 year of trastuzumab emtansine plus pertuzumab. Fisher, Julie 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy Policy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.